← 產業報告目錄
TNF Biosimilars Market Size, Share & Trends Analysis Report By Drug (Adalimumab Biosimilar, Infliximab Biosimilar, Certolizumab Biosimilar, Etanercept Biosimilar, and Golimumab Biosimilar), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy), Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-06頁數 180報告編號 INSIGHTACE-f439b1370a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide TNF Biosimilars Market is poised to register a CAGR of 16.5%.
TNF Biosimilars covers a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, supported by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global TNF Biosimilars Market Snapshot
Chapter 4. Global TNF Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global TNF Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on TNF Biosimilars Market Industry Trends
Chapter 5. TNF Biosimilars Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Adalimumab biosimilar
5.2.1.1. Amjevita
5.2.1.2. Yusimry
5.2.1.3. Cyltezo
5.2.1.4. Exemptia
5.2.1.5. Others (Products approved in developing countries & pipeline products)
5.2.2. Infliximab biosimilar
5.2.2.1. Avsola (infliximab-axxq)
5.2.2.2. Flixabi (SB2)
5.2.2.3. Inflectra (infliximab-dyyb)
5.2.2.4. Zessly
5.2.2.5. Others (Products approved in developing countries & pipeline products)
5.2.3. Certolizumab biosimilar
5.2.4. Etanercept biosimilar
5.2.4.1. Benepali
5.2.4.2. Nepexto
5.2.4.3. Eticovo
5.2.4.4. Erelzi
5.2.4.5. Others (Products approved in developing countries & pipeline products)
5.2.5. Golimumab biosimilar
Chapter 6. TNF Biosimilars Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Rheumatoid Arthritis
6.2.2. Psoriasis
6.2.3. Inflammatory Bowel Disease
6.2.4. Ankylosing Spondylitis
6.2.5. Others
Chapter 7. TNF Biosimilars Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Online Pharmacy
7.2.4. Others
Chapter 8. TNF Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global TNF Biosimilars Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.2.3. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.3.3. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.4.3. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.5.3. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.6.3. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alvotech
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Amgen
9.2.3. Amgen Inc.
9.2.4. AYUMI Pharmaceutica
9.2.5. Biocon
9.2.6. Biogen
9.2.7. Biosimilar Collaborations Ireland Limited
9.2.8. Boeheringer Ingelheim
9.2.9. Celltrion
9.2.10. Cipla
9.2.11. Coherus Biosciences
9.2.12. Cordavis Ltd.
9.2.13. Epirus Biopharmaceuticals
9.2.14. Fresenius Kabi
9.2.15. Glenmark Pharmaceuticals
9.2.16. Hanwha Chemical
9.2.17. Hetero
9.2.18. Innovent Biologics
9.2.19. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
9.2.20. LG Chem
9.2.21. Lupin
9.2.22. Mabpharm
9.2.23. Merck
9.2.24. Mylan
9.2.25. Nichi-Iko Pharmaceutical
9.2.26. Organon & Co.
9.2.27. Pfizer
9.2.28. Ranbaxy Laboratories (now Sun Pharma)
9.2.29. Samsung Bioepis
9.2.30. Sandoz
9.2.31. Shanghai CP Guojian Pharmaceutical
9.2.32. Sorrento Therapeutics (partner)
9.2.33. Stada Arzneimittel AG
9.2.34. Sunshine Guojian Pharmaceutical
9.2.35. Synermore
9.2.36. Teva
9.2.37. Torrent Pharmaceuticals
9.2.38. YL Biologics
9.2.39. Zydus Cadila
9.2.40. Other prominent players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們